The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review
- HCV reinfection, spontaneous clearance high among injection drug users. // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p17
The article discusses a study on hepatitis C virus reinfection and spontaneous clearance of reinfection among injection drug users in Australia as of December 2013.
- Hepatitis C Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities among Young Injection Drug Users in Chicago, 1997-1999. Thorpe, Lorna E.; Ouellet, Lawrence J.; Levy, Jennie R.; Williams, Ian T.; Monterroso, Edgar R. // Journal of Infectious Diseases;12/1/2000, Vol. 182 Issue 6
The prevalence, risk factors, and prevention opportunities of hepatitis C virus (HCV) in-fection were studied in a large sample of 698 young adult injection drug users (IDUs) in Chicago, 18-30 years old. Participants were recruited between 1997 and 1999 by using street outreach, targeted...
- Therapie der chronischen Hepatitis C. Schaffstein, Stella; Rampini, Silvana K.; Müllhaupt, Beat // Praxis (16618157);4/9/2014, Vol. 103 Issue 8, p423
No abstract available.
- Reply. Rimland, David; Guest, Jodie L.; Marston, Barbara // Clinical Infectious Diseases;2/1/2000, Vol. 30 Issue 2, p410
Responds to comments on a report by C.T. Staples and colleagues, which dealt with hepatitis C virus coinfection. HIV-infection risk factor; Prevalence of both intravenous drug abuse and hepatitis C virus infection.
- Potential HCV vaccine "highly economically attractive" in Canada. // PharmacoEconomics & Outcomes News;2/26/2005, Issue 472, p7
Discusses research being done on the economic aspects of a potential hepatitis C virus (HCV) vaccine in Canada. Reference to a study by M. D. Krahn and colleagues published in the February 18, 2005 issue of "Vaccine"; Assessment of the cost effectiveness of a potential HCV vaccine; Benefits of...
- Approach to the Patient with Chronic Hepatitis C Virus Infection. Herrine, Steven K. // Annals of Internal Medicine;5/21/2002, Vol. 136 Issue 10, p747
Chronic hepatitis C virus (HCV) infection is common and often asymptomatic. Antibodies against HCV are a highly sensitive marker of infection. Molecular testing for HCV is used to confirm a positive result on antibody testing and to provide prognostic information for treatment; however,...
- Factors associated with HIV and hepatitis C infection among regular and non-regular injection drug users in Baltimore. Graham, C. M.; Severtson, S. G.; Mitchell, M. M.; Floyd, L.; Latimer, W. W. // Retrovirology;2006 Supplement 1, Vol. 3, pP21
The article examines the association of HIV and hepatitis C infection prevalence and the length of time of regular injection drug use in Baltimore, Maryland. Regular users of intravenous drugs were more likely to be infected with hepatitis C virus (HCV) or HIV compared to short term injectors....
- HCV and HIV Counseling and Testing Integration in California: An Innovative Approach to Increase HIV Counseling and Testing Rates. Stopka, Thomas J.; Marshall, Clark; Bluthenthal, Ricky N.; Webb, David S.; Truax, Steven R. // Public Health Reports;May/Jun2007 Supplement, Vol. 122, p68
Objectives. In California, injection drug users (IDUs) comprise the second leading risk group for human immunodeficiency virus (HIV) infection and the majority of hepatitis C virus (HCV) cases. Innovative disease screening and prevention activities are needed to improve disease surveillance and...
- Improvements in data reporting needed to prevent, treat HCV/HBV in IDUs. // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p28
The article discusses research on the prevalence of hepatitis C virus infection among injection drug users, by Louisa Degenhardt and colleagues, published in "The Lancet."